How Mucor fungi use calcineurin and related proteins to cause infection

A novel link between calcineurin, amino acid permease, and protein kinase A in virulence in Mucor

NIH-funded research Texas Tech University Health Scis Center · NIH-11267982

Looking for fungal-only weak spots in Mucor infections that could lead to safer antifungal drugs for people with weakened immune systems.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionTexas Tech University Health Scis Center NIH-funded
Lab location1 site (Lubbock, United States)
Project IDNIH-11267982 on NIH RePORTER

What this research studies

This lab project studies the Mucor fungus, a cause of life‑threatening mucormycosis, to understand how the enzyme calcineurin and related proteins help the fungus grow and cause disease. Scientists will change fungal genes (including an amino acid permease) and measure how those changes affect growth, drug resistance, and signaling through protein kinase A in laboratory experiments. They will combine genetic, biochemical, and infection-model tests to find fungal-specific components downstream of calcineurin that do not exist in human cells. The goal is to identify targets that could be used to develop new antifungal medicines that avoid harming human cells.

Who could benefit from this research

Good fit: People who have had mucormycosis or are at high risk (for example, those with weakened immune systems) could be relevant for future sample donation or as eventual candidates for therapies stemming from this work.

Not a fit: People without fungal infections or unrelated medical conditions are unlikely to see direct benefit from this basic laboratory research in the near term.

Why it matters

Potential benefit: If successful, this work could point to new antifungal targets that lead to drugs which reduce death and disability from mucormycosis with fewer human side effects.

How similar studies have performed: Previous studies show calcineurin controls fungal virulence but direct calcineurin blockers harm humans, so pursuing fungal-specific downstream targets is promising but still exploratory.

Where this research is happening

Lubbock, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.